Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Evaluation of the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

This study has been completed.
Information provided by (Responsible Party):
Eisai Inc. Identifier:
First received: August 13, 2008
Last updated: February 11, 2016
Last verified: February 2016
The purpose of this study was to evaluate the safety and tolerability of perampanel (up to 12 mg/day) given as adjunctive treatment in subjects with refractory partial seizures and to evaluate the maintenance of effect of perampanel for the control of refractory partial seizures.

Condition Intervention Phase
Drug: perampanel
Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Studies to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Resource links provided by NLM:

Further study details as provided by Eisai Inc.:

Primary Outcome Measures:
  • Number of Participants With Treatment-emergent Non-Serious Adverse Events (AEs) and Treatment-emergent Serious Adverse Events (SAEs) [ Time Frame: From date of first dose of perampanel up to 30 days after the last dose of perampanel or up to approximately 5 years. ]
    An AE was defined as any untoward medical occurrence in a clinical investigation participant administered with an investigational product. A SAE was defined as any untoward medical occurrence that at any dose; resulted in death, was life-threatening (ie, the participant was at immediate risk of death from the AE as it occurred; this did not include an event that, had it occurred in a more severe form or was allowed to continue, might have caused death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or was as a congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug). In this study, treatment emergent AEs (defined as an AE (serious or non-serious) that started/increased in severity on/after the first dose of study medication up to 30 days after the final dose of study medication) were assessed.

Secondary Outcome Measures:
  • Median Percent Change in Seizure Frequency Per 28 Days Relative to Pre-Perampanel Baseline. [ Time Frame: Pre-perampanel Baseline and Weeks (1-13, 14-26, 27-39, 40-52, 53-65, 66-78, 79-91, 92-104, 105-117, 118-130, 131-143, 144-156, 157-169, 170-182, 183-195, 196-208, 209-221, 222-234, 235-247, and 248-260) ]
    Seizure frequency was derived from information (seizure count and type) recorded in participant diary. The seizure frequency per 28 days was calculated as the number of seizures divided by the number of days in the interval and multiplied by 28. The percent change in 28-day seizure frequency from pre-perampanel baseline was assessed for all partial-onset seizure types. The pre-perampanel baseline was defined as: (1) for participants who had been assigned to placebo treatment in the core DB study, the pre-perampanel baseline was computed from all data during the core DB study, and (2) for participants who had been assigned to perampanel in the core DB study, the pre-perampanel baseline was computed from the pre-randomization phase of the core DB study.

  • Percentage of Participants Who Experienced a 50% or Greater Reduction in Seizure Frequency Per 28 Days Relative to the Pre-Perampanel Baseline. [ Time Frame: Pre-perampanel Baseline and Weeks (1-13, 14-26, 27-39, 40-52, 53-65, 66-78, 79-91, 92-104, 105-117, 118-130, 131-143, 144-156, 157-169, 170-182, 183-195, 196-208, 209-221, 222-234, 235-247, 248-260) ]
    Seizure frequency was derived from information (seizure count and type) recorded in participant diary. The percentage of participants who experienced a 50% or greater reduction in seizure frequency per 28 days relative to the pre-perampanel Baseline(responders) was assessed. The pre-perampanel baseline was defined as: (1) for participants who had been assigned to placebo treatment in the core DB study, the Pre-perampanel baseline was computed from all data during the core Double-Blind (DB) study, and (2) for participants who had been assigned to perampanel in the core DB study, the pre-perampanel baseline was computed from the pre-randomization phase of the core DB study. The data is presented as percent responders.

Enrollment: 1218
Study Start Date: October 2008
Study Completion Date: September 2014
Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Perampanel
Participants previously receiving perampanel/placebo in the double blind-study, were titrated to receive perampanel 2 mg to 12 mg, once daily in the Open-Label Extension (OLE) study up to approximately 5 years.
Drug: perampanel
Perampanel 2 mg to 12 mg, once daily in the Open-Label Extension (OLE) study up to approximately 5 years

Detailed Description:
This was an open-label extension (OLE) study for subjects who completed one of the following double-blind, placebo-controlled, Phase 3 studies: E2007-G000-304 (NCT00699972), E2007-G000-305 (NCT00699582), and E2007-G000-306 (NCT00700310). This OLE study consisted of 2 phases: an Open-label Treatment Phase (comprised of a 16-week blinded Conversion Period and a 256-week Maintenance Period) and a Follow-up Phase (4 weeks). During the Conversion Period, subjects and investigators remained blinded to the treatment received in the previous DB study. To achieve this, all subjects continued to take 6 tablets of study medication (2 mg perampanel or matching placebo) or fewer as they were instructed during the core Double-Blind (DB) study. During the open-label Maintenance Period, subjects were treated with the perampanel dose that provided the best combination of individual efficacy and tolerability.

Ages Eligible for Study:   12 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Each participant who met the following criteria were enrolled in this study:

  1. Who completed Visit 8 of study E2007-G000-304, E2007-G000-305, or E2007-G000-306 and complied with the inclusion and exclusion criteria for that study (excluding criteria that are related to seizure occurrences).
  2. Provided written informed consent signed by participant or legal guardian prior to entering the study or undergoing any study procedures (If the written informed consent was provided by the legal guardian because the participant was unable to do so, a written or verbal assent from the participant was obtained).
  3. Who was considered reliable and willing to be available for the study period and record seizures and report adverse events them self or have a caregiver who can record and report the events for them.
  4. Females who were either of non-childbearing potential (defined as having undergone surgical sterilization, or postmenopausal [>age 50 and amenorrheic for 12 months]) or of childbearing potential. Females of childbearing potential were enrolled only if they agreed to be abstinent or continue using at least 1 medically acceptable method of contraception (eg, a double-barrier method [eg, condom + spermicide, condom + diaphragm with spermicide], IUD, or have a vasectomised partner) throughout the study period and for 2 months after the last dose of study drug. Women using hormonal contraceptives were required to use an additional approved method of contraception (as described previously) continuously throughout the entire study period and for 2 months after the last dose of study drug. (It was not required for male subjects to use contraceptive measures based on preclinical toxicology data).
  5. Continued to be treated with a stable dose of 1 or a maximum of 3 approved anti-epileptic drugs.

Exclusion Criteria:

Participants who met the following criteria were excluded from the study:

1. Those who, for any reason, discontinued early from the preceding double-blind study.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00735397

  Hide Study Locations
United States, Alabama
Birmingham, Alabama, United States, 35294
United States, Arizona
Phoenix, Arizona, United States, 85004
Phoenix, Arizona, United States, 85013
Tucson, Arizona, United States, 85724
United States, Arkansas
Little Rock, Arkansas, United States, 72205
United States, California
Fresno, California, United States, 93710
San Francisco, California, United States, 94115
Ventura, California, United States, 93003
United States, Colorado
Denver, Colorado, United States, 80218
Fort Collins, Colorado, United States, 80525
United States, District of Columbia
Washington, District of Columbia, United States, 20010
United States, Florida
Gulf Breeze, Florida, United States, 32561
Jacksonville, Florida, United States, 32209
Jacksonville, Florida, United States, 32224
Orlando, Florida, United States, 32819
Tallahassee, Florida, United States, 32308
Tampa, Florida, United States, 33609
United States, Georgia
Atlanta, Georgia, United States, 30342
Suwanee, Georgia, United States, 30024
United States, Idaho
Boise, Idaho, United States, 83702
United States, Indiana
Indianapolis, Indiana, United States, 46256
United States, Iowa
Ames, Iowa, United States, 50010
United States, Kentucky
Lexington, Kentucky, United States, 40536
United States, Louisiana
Houma, Louisiana, United States, 70363
United States, Maryland
Baltimore, Maryland, United States, 21287-7247
Bethesda, Maryland, United States, 20817
United States, Mississippi
Hattiesburg, Mississippi, United States, 39401
United States, Missouri
Chesterfield, Missouri, United States, 63017
Kansas City, Missouri, United States, 64111
Saint Louis, Missouri, United States, 63110
United States, New York
Albany, New York, United States, 12208
Buffalo, New York, United States, 14222
Great Neck, New York, United States, 11021
Lawrence, New York, United States, 11559
New York, New York, United States, 10016
Rochester, New York, United States, 14642
Syracuse, New York, United States, 13210
United States, North Carolina
Asheville, North Carolina, United States, 28806
United States, Ohio
Akron, Ohio, United States, 44308
Cincinnati, Ohio, United States, 45219
Columbus, Ohio, United States, 43221
Toledo, Ohio, United States, 43614
United States, Oklahoma
Tulsa, Oklahoma, United States, 74137
United States, Oregon
Portland, Oregon, United States, 97210
United States, Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Philadelphia, Pennsylvania, United States, 19107
United States, South Carolina
Charleston, South Carolina, United States, 29425
United States, Tennessee
Memphis, Tennessee, United States, 38105
United States, Texas
Dallas, Texas, United States, 75230
Dallas, Texas, United States, 75235
Dallas, Texas, United States, 75251
El Paso, Texas, United States, 79905
Houston, Texas, United States, 77030
United States, Utah
Salt Lake City, Utah, United States, 84108
United States, Virginia
Richmond, Virginia, United States, 23298
United States, Washington
Seattle, Washington, United States, 98104
United States, Wisconsin
Madison, Wisconsin, United States, 53715
Buenos Aires, Argentina, C1406FWY
Capital Federal, Argentina, 1428
Ciudad Autonoma de Buenos Aires, Argentina, C1117ABE
Ciudad Autonoma de Buenos Aires, Argentina, C1122AAK
Ciudad Autonoma de Buenos Aires, Argentina, C1182ACD
Ciudad Autonoma de Buenos Aires, Argentina, C1221ADC
Ciudad Autonoma de Buenos Aires, Argentina, C1280AEB
Cordoba, Argentina, X5000JJS
Cordoba, Argentina, X5010AOC
Guaymallen, Argentina, M5519FNF
La Plata, Buenos Aires, Argentina, B1902AHD
Lanus Oeste, Buenos Aires, Argentina, B1824CWE
Rosario, Argentina, S2000DSV
Salta, Argentina, A4402AYT
Tucuman, Argentina, T4000DVD
Australia, South Australia
Woodville, South Australia, Australia, 5011
Australia, Victoria
Fitzroy, Victoria, Australia, 3065
Heidelberg, Victoria, Australia, 3084
Parkville, Victoria, Australia, 3050
Graz, Austria, 8036
Innsbruck, Austria, 6020
Linz, Austria, A-4021
Bruxelles, Belgium, 1070
Leuven, Belgium, 3000
Ottignies, Belgium, 1340
Pleven, Bulgaria, 5800
Plovdiv, Bulgaria, 4002
Sofia, Bulgaria, 1113
Sofia, Bulgaria, 1606
Canada, Alberta
Calgary, Alberta, Canada, T2N 2T9
Canada, Ontario
London, Ontario, Canada, N6A 5A5
Toronto, Ontario, Canada, M5B 1T9
Canada, Quebec
Greenfield Park, Quebec, Canada, J4V 2J2
Santiago, Chile, 3459
Santiago, Chile, 8260094
Santiago, Chile, 8900085
Valdivia, Chile, 5090145
Beijing, China, 100730
Chengdu, China, 610041
Chongqing, China, 400016
Shanghai, China, 200040
Czech Republic
Olomouc, Czech Republic, 775 20
Praha 4, Czech Republic, 140 59
Praha 5, Czech Republic, 150 06
Tallinn, Estonia, EE-13419
Tartu, Estonia, EE-51014
Kuopio, Finland, FI-70210
Tampere, Finland, FI-33520
Bethune, France, 62408
Bron, France, 69677
Montpellier, France, 34295
Rennes, France, 35033
Toulouse, France, 31059
Berlin, Germany, 10117
Bernau, Germany, 16321
Bielefeld, Germany, 33617
Bonn, Germany, 53127
Dusseldorf, Germany, 40212
Erlangen, Germany, 91054
Gottingen, Germany, 37075
Kehl-Kork, Germany, 77694
Mainz, Germany, 55131
Marburg, Germany, 35039
Munchen, Germany, 81377
Ulm, Germany, 89081
Westerstede, Germany, 26655
Thessaloniki, Greece, 546 36
Thessaloniki, Greece, 57010
Hong Kong
Hong Kong, Hong Kong
Kowloon, Hong Kong
Pokfulam, Hong Kong, 852
Shatin, Hong Kong
Budapest, Hungary, 1097
Budapest, Hungary, 1136
Budapest, Hungary, 1145
Budapest, Hungary, H-1143
Kecskemet, Hungary, 6000
Hyderabad, India, 500001
Hyderabad, India, 500082
Jaipur, India, 302004
Mangalore, India, 575002
Mumbai, India, 400026
Nagpur, India, 440010
Nasik, India, 422004
New Delhi, India, 110060
Pune, India, 411011
Pune, India, 411030
Visakhapatnam, India, 530002
Ashkelon, Israel, 78278
Haifa, Israel, 31096
Holon, Israel, 58100
Kfar Saba, Israel, 44281
Petach Tikva, Israel, 49202
Ramat Gan, Israel, 52621
Firenze, Italy, 50134
Genova, Italy, 16147
Milano, Italy, 20121
Milano, Italy, 20133
Napoli, Italy, 80131
Korea, Republic of
Busan, Korea, Republic of, 614735
Daegu, Korea, Republic of, 700712
Pusan, Korea, Republic of, 602715
Seoul, Korea, Republic of, 110744
Seoul, Korea, Republic of, 120752
Seoul, Korea, Republic of, 135710
Seoul, Korea, Republic of, 138736
Riga, Latvia, LV-1004
Riga, Latvia, LV-1038
Valmiera, Latvia, LV-4201
Kaunas, Lithuania, LT-50009
Klaipeda, Lithuania, LT-92288
Vilnius, Lithuania, LT-08661
Kuala Lumpur, Malaysia, 59100
Kuala Terengganu, Malaysia, 20400
Aguascalientes, Mexico, 20127
Mexico City, Distrito Federal, Mexico, 14050
Monterrey, Nuevo Leon, Mexico, 64000
San Luis Potosi, Mexico, 78240
Heeze, Netherlands, 5591 VE
Zwolle, Netherlands, 8025 BV
Ermita, Philippines, 1000
Makati City, Philippines, 1229
Bialystok, Poland, 15-276
Gdansk, Poland, 80-803
Gdansk, Poland, 80-952
Katowice, Poland, 40-635
Lublin, Poland, 20-718
Warszawa, Poland, 02-957
Coimbra, Portugal, 3000-075
Lisboa, Portugal, 1649-035
Porto, Portugal, 4200-319
Bucharest, Romania, 20125
Bucharest, Romania
Russian Federation
Ekaterinburg, Russian Federation, 620149
Kazan, Russian Federation, 420097
Moscow, Russian Federation, 107066
Moscow, Russian Federation, 107076
Moscow, Russian Federation, 119992
Moscow, Russian Federation, 125412
Nizhniy Novgorod, Russian Federation, 603005
Omsk, Russian Federation, 644001
Samara, Russian Federation, 443095
Smolensk, Russian Federation, 214018
Tyumen, Russian Federation, 625039
Yaroslavl, Russian Federation, 150030
Belgrade, Serbia, 11000
Nis, Serbia, 18000
Novi Sad, Serbia, 21000
South Africa
Johannesburg, Gauteng, South Africa, 2196
Cape Town, Western Cape, South Africa, 7925
Cape Town, South Africa, 7500
Granada, Andalucia, Spain, 18012
Badalona, Cataluna, Spain, 8916
Barcelona, Cataluna, Spain, 8003
Barcelona, Cataluna, Spain, 8025
Valencia, Comunidad Valenciana, Spain, 46009
Alcorcon, Madrid, Communidad de, Spain, 28922
Madrid, Madrid, Communidad de, Spain, 28040
Baracaldo, Pais Vasco, Spain, 48903
Goteborg, Sweden
Linkoping, Sweden
Kaohsiung, Taiwan, 833
Taichung, Taiwan, 40705
Tainan, Taiwan, 70403
Taoyuan, Taiwan, 333
Bangkok, Thailand, 10330
Bangkok, Thailand, 10400
Bangkok, Thailand, 10700
Chiangmai, Thailand, 50200
Muang, Thailand, 40002
Donetsk, Ukraine, 83052
Donetsk, Ukraine, 83114
Kharkiv, Ukraine, 61018
Kharkiv, Ukraine, 61068
Kyiv, Ukraine, 4080
Kyiv, Ukraine, 4209
Lviv, Ukraine, 79010
Uzhgorod, Ukraine, 88000
United Kingdom
Liverpool, United Kingdom, L9 7LJ
London, United Kingdom, SW17 0QT
Middlesbrough, United Kingdom, TS4 3BW
Stoke-on-Trent, United Kingdom, ST4 7LN
Sponsors and Collaborators
Eisai Inc.
Study Director: Michelle Gee, PhD. Eisai Limited
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Eisai Inc. Identifier: NCT00735397     History of Changes
Other Study ID Numbers: E2007-G000-307
Study First Received: August 13, 2008
Results First Received: September 16, 2015
Last Updated: February 11, 2016

Keywords provided by Eisai Inc.:
Partial onset seizures

Additional relevant MeSH terms:
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms processed this record on May 23, 2017